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Identifying the targets of bioactive compounds is
a major challenge in chemical biological research.
Here, we identified the functional target of the natu-
ral bioactive compound glucopiericidin A (GPA)
through metabolomic analysis. We isolated GPA
while screening microbial samples for a filopodia
protrusion inhibitor. Interestingly, GPA alone did
not inhibit filopodia protrusion, but synergistically
inhibit protrusion with the mitochondrial respiration
inhibitor, piericidin A (PA). These results suggested
that GPA might inhibit glycolysis. Capillary electro-
phoresis time-of-flight mass spectrometry (CE-
TOFMS) provided strong evidence that GPA sup-
presses glycolysis by functionally targeting the
glucose transporter. GPA may therefore serve as a
glucose transporter chemical probe. Simultaneous
inhibition of both glycolysis and mitochondrial respi-
ration dramatically decreased intracellular ATP
levels, indicating that GPA inhibits ATP-dependent
filopodia protrusion with PA. Our results represent
a challenge of molecular target identification using
metabolomic analysis.
INTRODUCTION
To fully understand the regulation of cellular events (e.g., cell
growth, survival, migration), functional analysis of each protein
involved in the regulatory systems is required (Pandey and
Mann, 2000). Genetic studies utilizing chemical inhibitors are
among the best approaches to investigate protein function
(Alaimo et al., 2001; Zheng and Chan, 2002). Chemical inhibitors
can be used to modulate the function of target proteins in a
manner analogous to the engineering of mutations in molecular
genetic studies (Alaimo et al., 2001; Fenteany et al., 1995; Liu
et al., 1991). Many chemical inhibitors are available, though there
are far fewer than the number of proteins involved in the com-
plicated regulation of cellular events. Therefore, new chemical
inhibitors must be developed in order to advance the applica-Chemistry & Biology 17, 989–9bility of chemical genetic studies to the functional analysis of
proteins.
The structural diversity of natural products makes them ideal
screening sources for chemical inhibitors that can be used to
dissect the complex molecular mechanisms underlying cellular
events through chemical genetics (Abel et al., 2002; Newman
and Cragg, 2007). One strategy for screening natural products
for new chemical inhibitors is the cell-based assay (Hart,
2005). However, identifying the target of a molecular inhibitor
isolated by cell-based assays represents a crucial hurdle that
must be overcome before chemical genetic studies can
commence.
There are two fundamental approaches to identify chemical
inhibitor targets: direct and indirect (Hart, 2005). In the direct
approach, the target proteins bound to the inhibitor are purified
and directly identified by mass spectrometry. In this approach,
chemical synthesis of the inhibitor compound onto immobilized
beads or a column is required for affinity purification of the
binding proteins. However, in some cases, the chiral centers
and unique structural scaffolds of natural products make
synthesis difficult.
The indirect approach to chemical inhibitor target identifica-
tion involves searching for candidates by profiling biological
data. If the compound was found to perturb some cellular event
for which the regulatory signaling pathway is known, targets can
be revealed by examining the effect of the compound on each
step of the pathway. In some cases, omics studies (e.g., proteo-
mics, transcriptomics, metabolomics) can aid the comprehen-
sive investigation of a compound’s effect on the potentially large
numbers of biological steps (Hart, 2005).
We employed an indirect approach, using metabolomics to
identify the chemical inhibitor derived from natural product
screening. Metabolomics technologies have advanced tremen-
dously in recent years, and capillary electrophoresis time-
of-flight mass spectrometry (CE-TOFMS) has emerged as a
powerful new tool for the comprehensive analysis of cellular
metabolites (Monton and Soga, 2007; Soga et al., 2003). The
use of CE-TOFMS to understand global metabolism at the
system level has become widespread (Hirayama et al., 2009;
Ishii et al., 2007; Soga et al., 2006; Sugimoto et al., 2009). Anal-
ysis of themetabolome with CE-TOFMS also revealed metabolic
changes induced by drug compounds (Soga et al., 2006). Thus,
despite a lack of reports describing the identification of chemical98, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 989
Table 1. Inhibitory Activities of Remixing Silica Gel Chromatography Fractions, and the Effect of Withholding Each Fraction from the
Remix
Sample #
Fractions Eluted with CHCl3: MeOH
Filopodia Protrusion
100: 0 100: 1 100: 2 100: 5 100: 10 100: 30
I II III IV V VI
Remix Contained Contained Contained Contained Contained Contained Inhibition
Remix – I Contained Contained Contained Contained Contained No inhibition
Remix – II Contained Contained Contained Contained Contained Inhibition
Remix – III Contained Contained Contained Contained Contained Inhibition
Remix – IV Contained Contained Contained Contained Contained No inhibition
Remix – V Contained Contained Contained Contained Contained Inhibition
Remix – VI Contained Contained Contained Contained Contained Inhibition
I + IV Contained Contained Inhibition
I Contained No inhibition
IV Contained No inhibition
See Figure S1 for the bioassay-guided isolation of the compounds.
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be worthwhile.
We began our investigation by conducting a natural product
screening to isolate bioactive compounds that inhibit cellular
filopodia protrusion in the carcinoma. Filopodia are spike-like
cell membrane projections contributing to tumor metastasis;
however, the molecular mechanisms controlling filopodia pro-
trusion are complicated and unclear (Faix and Rottner, 2006;
Mattila and Lappalainen, 2008). Finding a filopodia inhibitor in
carcinoma and its molecular target that could be employed in
chemical genetic studies may therefore lead to a fuller under-
standing of filopodia contributing to the treatment of tumor
metastasis (Bacon et al., 2007; Shulman et al., 2009). Here, we
describe the isolation of a new chemical inhibitor of filopodia
protrusion through natural product screening, and identification
of the inhibitor’s target by metabolomic analysis. This is the
first report to our knowledge on natural product target molecule
identification using a metabolomic approach.
RESULTS
Screening and Isolation of the Inhibitor of Filopodia
Protrusion
Human epidermal carcinoma A431 cells highly express the
epidermal growth factor (EGF) receptor. In response to EGF
stimulation, these cells become highly chemotactic (Rabinovitz
et al., 1999). Within 30 min of EGF stimulation, A431 cells
protrude large spike-like filopodia that can be easily observed
under a microscope. We used this simple assay system to iden-
tify compounds from microbial sources that inhibited filopodia
protrusion.
After screening over 3000 microbial broth samples, we found
that one broth from Lechevalieria sp. strain 1869-19 strongly
inhibited EGF-induced filopodia protrusion in A431 cells (see
Figure S1A available online).
To isolate the potential inhibitors in this broth, the broth
extracts was separated into six fractions, numbered I–VI, by
silica-gel chromatography with chloroform-methanol elution.
However, no single fraction showed inhibitory activity against990 Chemistry & Biology 17, 989–998, September 24, 2010 ª2010 Elfilopodia protrusion (Figure S1B). To examine whether the active
substance may have degraded during chromatography, all
six fractions were remixed (recombined fractions were termed
‘‘Remix’’) and tested for inhibitory activity. The Remix inhibited
EGF-induced filopodia protrusion in the same concentration
range as the broth extract (Figure S1C). These results suggested
that the inhibition of EGF-induced filopodia protrusion was due
to the synergistic action of two (or more) substances in the broth
extract, and that these ‘‘active’’ substances were separated into
different fractions during silica gel chromatography.
To determine which of the six fractions contained each active
substance, we prepared remixes with one fraction withdrawn
and assessed each such remix for ability or inability to inhibit
filopodia protrusion. Withdrawal of fractions I (eluted from silica
gel column by 100:0 chloroform:methanol) and IV (eluted by
100:5 chloroform:methanol) from the Remix resulted in no inhi-
bition of filopodia protrusion (Table 1; Figure S1D), indicating
that fractions I and IV contained active substances. Further-
more, combining fractions I and IV restored the inhibitory
activity to a level comparable to the complete Remix, indicating
that the mixture of the active substances in fractions I and
IV was sufficient for inhibition of EGF-induced filopodia
protrusion.
To identify the active substances in fractions I and IV, further
isolation processes were undertaken. Fraction IV was subjected
to silica gel column chromatography with toluene-acetone
elution. Each resulting fraction was assessed for its ability to
inhibit filopodia protrusion in the presence of fraction I. Fractions
eluted with a toluene-acetone mixture at a 3:1 ratio demon-
strated inhibition in the presence of fraction I, but not in
its absence. Fractions showing the filopodia inhibition were
collected and further purified by centrifugal liquid-liquid partition
chromatography (CPC) using chloroform-methanol-water (5:4:6,
ascending mode) elution, yielding a colorless, amorphous
product. Analysis of MS and NMR spectra identified the product
as glucopiericidin A (GPA) (Matsumoto et al., 1987) (Figure 1A).
The active substance in fraction I was purified by CPC using
hexane-ethyl acetate-acetonitrile (5:1:4, ascending mode) elu-
tion, yielding pure yellow oil. This product was identified by MSsevier Ltd All rights reserved
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Figure 1. Synergistic Inhibition of Filopodia Protrusion by Cotreat-
ment with GPA and PA
(A) Planar structures of GPA and PA.
(B) Synergistic inhibitory activity of GPA and PA in combination against filopo-
dia protrusion in A431 cells. Cells were treated with varied concentrations of
PA and GPA for 30 min and then stimulated by EGF (30 ng ml-1) for 30 min
to protrude filopodia (as shown by arrowheads in control picture above).
Frameless photos indicate cells with filopodia, while the framed photos indi-
cate cells in which filopodia protrusion was inhibited. Note that cotreatment
with GPA and PA inhibited filopodia protrusion while single treatment with
each did not, indicating that GPA and PA act synergistically. Photos represent
the results of three independent experiments.
(C) Quantification of inhibition of filopodia protrusion by GPA and PA cotreat-
ment. The number of A431 colonies with filopodia were determined micro-
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Chemistry & Biology 17, 989–9and NMR as piericidin A (PA) (Hall et al., 1966) (Figure 1A). The
final purification procedure is described in Figure S1E.
Next, we examined the inhibitory activity of GPA and PA
against filopodia protrusion (Figures 1B and 1C). Neither GPA
nor PA alone, at concentrations up to 500 nM and 2.3 mM,
respectively, showed inhibitory activity (see also Figure S1F).
When combined, however, much lower concentrations of GPA
(17 nM) and PA (0.68 nM) produced inhibition of filopodia pro-
trusion. Hence, we isolated two natural products that inhibit
EGF-induced filopodia protrusion in a synergistic manner.
PA-Mediated Inhibition of Mitochondrial Respiration
Is Necessary for Inhibition of Filopodia Protrusion
Next, we investigated the mechanisms underlying the syner-
gistic inhibition of filopodia protrusion using cotreatment with
GPA and PA. Since PA is a known inhibitor of the mitochondrial
respiratory chain complex I (Gutman et al., 1970; Hall et al.,
1966), we hypothesized that inhibition of mitochondrial respira-
tion by PA was required for the observed synergistic inhibition
of filopodia protrusions when cells were cotreated with GPA
and PA. To test this hypothesis, we examined whether other
inhibitors of mitochondrial respiration would inhibit filopodia
protrusion in combination with GPA. As expected, rotenone,
another complex I inhibitor, showed the synergistic inhibition in
combination with GPA (Figure 2A). In addition, antimycin A,
a mitochondrial respiratory chain complex III inhibitor, and oligo-
mycins, complex V inhibitors, also inhibited filopodia protrusion
synergistically with GPA (Figure 2A). These results suggested
that suppression of mitochondrial respiration is responsible
for the synergistic filopodia inhibition seen with GPA and PA.
Conversely, although GPA is the glucopyranoside derivative of
PA, GPA showed low inhibitory activity against mitochondrial
respiration (about 500-fold weaker than PA) (see Figure S2).
The weak inhibition of mitochondrial respiration suggested that
GPA must contribute to inhibition of filopodia protrusion through
a different mode of action.
Elucidating GPA’s Mode of Action through CE-MS
Metabolomics
We conducted chemical genomic screening to investigate the
mode of action whereby GPA contributes to the inhibition of
filopodia protrusion. In this screening, the biological profile of
target-identified inhibitors of filopodia inhibition was compared
with that of GPA in order to find target-identified inhibitors with
the same bioactivity as GPA, considering the possibility that
GPA might target the same molecules as these other inhibitors.
About 200 target-identified compounds were assessed for their
ability to inhibit EGF-induced filopodia protrusion in the presence
of PA (Table S2). As a result of this analysis, we found that
2-deoxyglucose (2DG), a known suppressor of glycolysis (Bach-
elard et al., 1971), was the sole compound able to inhibit protru-
sion in combination with PA (Figure 2B).scopically, and the rate of inhibition [filopodia colonies] / [total colonies] in
a field was calculated. Error bars represent ± SD (n = 9). The same result
was obtained in duplicate.
See also Figure S1 and Table S1 for the supporting data on the bioassay-
guided isolation, the structural identification, and the bioactivity of GPA
and PA.
98, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 991
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Figure 2. Mechanistic Insights into Syner-
gistic Inhibition of Filopodia Protrusion by
GPA and PA
(A) Synergistic inhibition of filopodia protrusion by
inhibitors of mitochondrial respiration in the pres-
ence of GPA. Mitochondrial inhibitors with similar
activity to PA also inhibited filopodia protrusion in
the presence of GPA. Mitochondrial inhibitors
RTN (rotenone: another inhibitor of complex I),
AMA (antimycin A: complex III inhibitor), and OM
(oligomycins: complex V inhibitor) were used.
(B and C) GPA appears to suppress glycolysis.
Through chemical genomic screening of target-
identified inhibitors, we found that the hexokinase
inhibitor 2DG alone synergistically inhibited filopo-
dia protrusion in the presence PA, similar to
the effect observed with GPA (for B) the entire
screening results are shown in Table S2). Since
hexokinase inhibition by 2DG would suppress
glycolysis, this suggested that glycolytic suppres-
sionmight be responsible for the synergistic inhibi-
tion of filopodia protrusion with PA, and that there-
fore GPA might also suppress glycolysis. This
validity of this hypothesis was supported by the
result demonstrating that GPA decreases cellular
ATP in the presence of the mitochondrial respira-
tion inhibitor PA (C), since it is known that glyco-
lytic suppression causes a drastic decrease in
cellular ATP under the suppression of mitochon-
drial respiration. Error bars: SD (n = 3).
The respiratory inhibition by PA and the weak inhi-
bition by GPA are shown in Figure S2.
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involved in the synergistic inhibition of filopodia protrusion seen
with PA. Additionally, filopodia protrusion has been described as
an ATP-dependent process (Le Clainche and Carlier, 2008).
Thus, we hypothesized that PA and 2DG inhibit filopodia pro-
trusion by decreasing cellular ATP levels through simultaneous
blockage of two ATP-producing metabolic pathways: glycolysis
(2DG) and mitochondrial respiration (PA). In support of this
hypothesis, we found that 2DG did indeed decrease cellular
ATP levels synergistically with PA (Figure 2C). We therefore sus-
pected that GPA might also decrease cellular ATP levels, result-
ing in inhibition of filopodia protrusion in the same manner as
2DG. As shown in Figure 2C, treatment of A431 cells with GPA
also caused a drastic decrease in cellular ATP with PA, suggest-
ing that GPA might perturb the ATP-producing metabolic path-
ways, most likely glycolysis, resulting in the filopodia protrusion
inhibition in the presence of PA.
One possible approach to address the issue of whether GPA
actually perturbs glycolysis is to assess the effect of GPA on
global metabolism and on glycolysis in particular, by measuring992 Chemistry & Biology 17, 989–998, September 24, 2010 ª2010 Elsevier Ltd All rights resethe metabolome using CE-TOFMS. In
CE-TOFMS, metabolites are separated
by capillary electrophoresis (CE) on the
basis of their charge and size, and then
detected as peaks in MS (Soga et al.,
2003). Metabolites are identified by
comparing CE migration time and molec-
ular weight with that of standards, and arequantified by peak intensity in reference to standard calibration
curves. We used this approach to quantitatively examine the
differences in metabolite levels between control and GPA-
treated cells.
Using the CE-TOFMS approach, we detected around 4000
(3853–4848) peaks in each sample (control and GPA-treated,
n = 4). A reference set of 112 standards was used to identify
the metabolites of glycolysis and related pathways (pentose
phosphate pathway, TCA cycle, nucleotide synthesis, amino
acid, and others, see Figure 3). A total of 83 peaks were quanti-
tatively identified, and 24 metabolites were found to significantly
differ between control and GPA-treated samples (for the entire
list with exact p values, see Table S3), which are mapped in
the overview in Figure 3 (pathway information was obtained
by reference to KEGG [http://www.genome.jp/kegg/pathway.
html]).
Our results showed that GPA significantly decreased the
amount of glycolytic end products (pyruvate: 61.5%, p = 3.8 3
105 and lactate: 40.3%, p = 1.4 3 105). Moreover, another
glycolytic parameter, the lactate/pyruvate ratio, was alsorved
Figure 3. Snapshot Picture of GPA-Changed Metabolome
The global metabolites in GPA-treated A431 cells (30 min treatment) were extracted and analyzed by CE-TOFMS, and compared with that of control cells. Signif-
icantly decreasedmetabolites in GPA-treated cells are shown as , , and (fold decrease >50%, >25%, and <25%, respectively), and significantly increased
metabolites are shown as , , and (fold increase <200%, <400%, and >400%, respectively). Significance was determined by Student’s t test (n = 4,
p < 0.05). The entire set of results with exact p values and list of metabolite abbreviations are listed in Table S3. (See also Figure S3 for lactate/pyruvate ratio.)
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gested that GPA-inhibited glycolysis.
GPA Targets Glucose Uptake
Upondetermining thatGPA inhibits glycolysis, we then examined
which reaction step in glycolysiswasblockedbyGPAas ameans
of identifying the GPA target. To reveal particular GPA-induced
changes in glucose metabolism, control and GPA-treated A431
cells were treated with [1,2,3,4,5,6-13C]-glucose (full-label), and
then the [13C]-incorporated metabolites within those cells were
quantified by CE-MS. Incorporation of [13C]-labeled glucose
into any metabolites of glycolysis was decreased in GPA-treated
cells (Figure 4; Table S4), indicating that the glycolytic influx
was lowered by GPA treatment. Since the metabolite closest
to glucose in the glycolytic pathway is glucose-6-phosphate
(G6P), these results suggest that GPA acts on the steps pro-
ceeding from glucose uptake to G6P production.
Since hexokinase catalyzes G6P production, we examined
the effect of GPA on hexokinase activity in vitro. Glucose, as
a substrate of hexokinase, was mixed with reaction buffer
containing partially purified hexokinase, G6PDH, and NADP asChemistry & Biology 17, 989–9a coenzyme of the G6PDH reaction, and incubated at room
temperature (Bergmeyer, 1963; Floridi et al., 1981). In this reac-
tion, the G6P produced by hexokinase is further hydrolyzed
by G6PDH, with the accompanying conversion of NADP to
NADPH, so that hexokinase activity can be estimated by the
spectrophotometric absorbance of NADPH (Bergmeyer, 1963).
As shown in Figure 5A, the assay revealed that addition of
glucose led to an increase in the amount of NADPH, which could
be negated by the hexokinase inhibitor 2DG. However, GPA at
concentrations up to 1.7 mM failed to inhibit the reaction, indi-
cating that the hexokinase reaction step is not the point of inhi-
bition of glycolysis through a decrease in the amount of G6P
by GPA.
Another possible step that GPA could act upon to cause
a decrease in G6P is glucose uptake. To examine this possibility,
we treated cells with [3H]-2DG and evaluated whether GPA
would affect glucose uptake. The compound 2DG acts as
a glucose mimic and is incorporated into cells by glucose
transporters. However, 2DG cannot be catabolized in glycolysis;
thus, the amount of 2DG that is taken up simply reflects the
glucose uptake capacity of a cell’s glucose transporters.98, September 24, 2010 ª2010 Elsevier Ltd All rights reserved 993
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Figure 4. [13C]-Labeling Study
[13C]-glucose was incorporated into A431 cells for 30 min immediately after
GPA treatment. All detected major isotopomers ([13C]-glucose-6-phosphate
and its [13C]-metabolites) were decreased by GPA treatment (the entire list is
shown in Table S4), indicating that GPA inhibits the step from [13C]-glucose
uptake to [13C]-glucose-6-phosphate production. Error bars: SD (n = 4).
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a dose dependent manner (Figure 5B), with an IC50 of 4.9 ±
2.9 nM (mean ± SE, n = 3). This concentration was quite similar
to the concentration of GPA required to inhibit EGF-induced
filopodia protrusion in combination with PA (Figures 1B and
1C). It is reported that GLUT1 is responsible for glucose uptake
in A431 cells (Aloj et al., 1999). Treatment of cells with GPA did
not change the expression level of GLUT1 in the plasma mem-
brane (Figure S5A), which suggests that GPA inhibits GLUT1
function.
To confirm whether GPA does in fact inhibit GLUT1 function,
GLUT1 was overexpressed in cells (Figure S5B), and the sensi-
tivity of cells to GPA upon 2DG uptake was evaluated. Uptake
of 2DG was substantially increased (about 4-fold) by GLUT1
overexpression (expression level was shown in Figure S5B).
Although GPA could inhibit 2DG uptake in GLUT1-overexpress-
ing cells, when compared with vector control cells, GLUT1-over-
expressing cells became less sensitive to GPA depending on the
expression level of GLUT1 (Figure 5C). The IC50 value for 2DG994 Chemistry & Biology 17, 989–998, September 24, 2010 ª2010 Eluptake increased with GLUT1 expression (21.6 ± 7.7 nM,
[mean ± SE, n = 3) in vector control cells versus 108 ± 24 nM
(mean ± SE, n = 3) in GLUT1-overexpressing cells). These results
indicated that GPA inhibits GLUT1 function, and thereby inhibits
glycolysis.
DISCUSSION
In this study, we conducted natural product screening to isolate
the inhibitor of EGF-induced filopodia protrusion. Natural prod-
ucts have historically provided a variety of important bioactive
compounds, such as antibiotics, immunosuppresants, and
antitumor agents (Abel et al., 2002; Lokey, 2003; Newman and
Cragg, 2007). Natural product screening has also led to
discovery of unique bioactive compounds useful in chemical
genetic research (e.g., FK506 [Liu et al., 1991] and lactacystin
[Fenteany et al., 1995]). Natural products often contain unique
structures and chiral centers, which anecdotal evidence sug-
gests are important for the unique bioactivity and target recog-
nition of many compounds. We therefore conducted natural
product screening in microorganisms to isolate and characterize
an inhibitor of filopodia protrusion.
As a result of our screening studies, we found that the cultured
broth of Lechevalieria sp. strain 1869-19 contained compounds
that inhibited EGF-induced filopodia protrusion (Figure 1A).
However, this inhibition required the synergistic effect of two
compounds (Figures S1D and S1E), which were isolated and
identified as GPA and PA (Figures 1A–1C).
We then examined the mechanism underlying the synergistic
inhibition of filopodia protrusion caused by GPA and PA. PA is
a well-known inhibitor of respiratory complex I in mitochondria
(Gutman et al., 1970). Because other mitochondrial respiratory
inhibitors, such as antimycin A and oligomycins, inhibited filopo-
dia protrusion only in the presence of GPA, inhibition of mito-
chondrial respiration by PA could be responsible for the syner-
gistic inhibition of GPA and PA (Figure 2A). Little is known
about GPA however. There are few reports in the literature that
describe the biological activities of GPA (Ahn et al., 1995; Matsu-
moto et al., 1987), and its molecular target(s) and mode of
action have not been determined. To address this issue, we
employed a chemical genomic approach, in which a target-
identified chemical library was searched to find compounds
with activity similar to GPA. The compound 2-deoxy-glucose
(2DG) was identified using this approach (Figure 2B; Table S2).
Because 2DG is known to inhibit glycolysis by inhibiting the
enzyme hexokinase, GPA would be expected to also inhibit
glycolysis. By means of metabolomic analysis using CE-TOFMS
(Figure 3) in combination with an evaluation of [13C]-labeled
glycolytic metabolites (Figure 4), we clearly determined that
GPA disrupts glycolysis by inhibiting the initial step of the
pathway. Finally, we have also clarified that glucose transporters
are functional target proteins of GPA (Figure 5).
Glucose transporters comprise a large family of transmem-
brane proteins characterized by having different affinities for
glucose (Mueckler et al., 1985; Scheepers et al., 2004). Among
glucose transporters, GLUT1 has a high affinity for glucose
and is one of the most abundantly expressed transporters in
many types of tumors (Scheepers et al., 2004). Indeed, A431
cells used in this study have been reported to express onlysevier Ltd All rights reserved
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Figure 5. GPA-Mediated Inhibition of Glucose Uptake via GLUT
(A) GPA failed to inhibit the in vitro hexokinase enzyme reaction. Previously,
hexokinase activity was successfully monitored by addition of the hexokinase
substrate glucose, causing an increase in enzymatic activity (detected by
NADPH absorbance at 340 nm), which was inhibited by 2-deoxyglucose.
However, GPA could not inhibit this increase in hexokinase activity, indicating
that GPA was not a hexokinase inhibitor. Error bars: SD (n = 3).
(B) Inhibition of glucose uptake by GPA. GPA inhibited the uptake of the
glucose mimic 2-deoxyglucose (2DG) in a dose-dependent manner. Error
bars: SD (n = 3). Similar results were obtained from three individual experi-
ments. These results explain the glucose-6-phosphate decrease depicted in
Figure 4.
(C) Inhibition of GLUT1-mediated glucose uptake by GPA. Since glucose
uptake in A431 cells is primarily mediated by GLUT1, A431 GLUT1 was over-
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Chemistry & Biology 17, 989–9GLUT1 as glucose transporter (Aloj et al., 1999). Therefore, data
accumulated in this study suggest that there are only three likely
mechanisms that could explain glucose uptake inhibition by
GPA: (i) GPA mimics the GLUT1 substrate, (ii) inhibition of
GLUT1 translocation into the cell membrane, and (iii) lowering
the expression level of GLUT1. We ruled out the last two possi-
bilities by immunoblotting, as shown in Figure S5A. The data
showing that the level of GLUT1 expression was not changed
in the membrane fraction by GPA treatment suggest that uptake
inhibition by GPA was not due to an inhibition of GLUT1 translo-
cation or a reduction in GLUT1 expression. Moreover, GPA
possesses the glucose moiety, and glucose null derivative PA
failed to inhibit the uptake (Figure S5C). Thus, it is likely that
the glucose uptake inhibition by GPA would be due to its gluco-
pyranosidemoiety, perhaps by functioning as a glucosemimic to
GLUT1. This suggests that GLUT1 would be the bona fide target
of GPA due to GPA’s inhibition of glycolysis in A431 cells.
Our overexpression study confirmed GPA inhibits glucose
uptake via GLUT1 in A431 cells, but we also tested GPA against
another glucose transporter, GLUT4 in Swiss 3T3 cells. Differen-
tiated Swiss 3T3-L1 adipocytes take up glucose basally via
GLUT1. However, when 3T3-L1 adipocytes are stimulated with
insulin, GLUT4 is translocated to the membrane (Saito et al.,
2007), and both GLUT1 and GLUT4 transport glucose into the
cells. GPA inhibited both the basal uptake of [3H]-2DG via
GLUT1 and the increased uptake of glucose in insulin-stimulated
cells (Figure S5D), suggesting that GPA inhibits glucose uptake
via both GLUT1 and GLUT4.
The glucose transporter inhibitors cytochalasin B and phloritin
are known to suppress glucose uptake at mM and mM con-
centrations, respectively. GPA, on the other hand, inhibits
glucose uptake in A431 cells, Swiss 3T3-L1 adipocytes, and
GLUT1-overexpressed HEK293T cells at nanomolar concentra-
tions (Figures 5B and 5C; Figure S5D). Thus, ours is the first
report to our knowledge of aGLUT inhibitor capable of suppress-
ing glucose uptake at nanomolar concentrations.
Aside from its influence on glycolysis, GPA treatment also
leads to changes in the amounts of TCA cycle intermediates,
as well as increases in levels of aspartate and asparagine (Fig-
ure 3; Table S3). We believe these changes may be caused in
a part by GPA-limited entry of pyruvate into the citrate cycle,
which might slow the rate at which oxaloacetate is converted
to citrate. Slowing the conversion of oxaloacetate may lead to
accumulation of preceding TCA cycle intermediates such as
malate, fumarate, and succinate.
Reports suggest that active glutaminolysis takes place in the
metabolome of tumor cells (Deberardinis et al., 2007), described
as anaplerotic ATP energy fueling through ‘‘truncated’’ TCA
metabolism (from 2-oxoglurate to malate) without pyruvate
entry (Parlo and Coleman, 1984; Piva and McEvoy-Bowe,
1998). In tumor glutaminolysis, highly incorporated glutamine is
converted into glutamate and then into 2-oxoglutarate via aspar-
tate transaminase, with production of aspartate as a byproductexpressed, and the sensitivity of glucose uptake to GPA was examined. Over-
expression lowered the sensitivity 2DG uptake inhibition by GPA as observed
with the shift of the inhibition curve to the right. Error bars: SD (n = 3). The data
shown represent results of three independent experiments.
(See also Figure S5.)
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be excluded that these changes in the amounts of TCA cycle
intermediates and aspartate are caused by glutaminolysis in
addition to GPA-suppressed pyruvate entry into the TCA cycle
(Kovacevic et al., 1987).
CE-MSmetabolome analysis is a powerful technique that may
help elucidate the targets of the compounds, in the case the
compounds impact glycolysis. Glutaminolytic analyses, and
labeling studies using [13C]-glutamine in combination with CE-
TOFMS—analogous to our studies of GPA’s effect on glycolytic
pathways—might clarify the target-unverified compounds that
disturb glutaminolysis. Chemical metabolomic analyses should
therefore be encouraged, not only because they may further
understanding of the physiological and pathological effects of
many natural products, but also because such studies may
enhance development of compounds that may serve as a new
class of anticancer drugs which regulate the tumor metabolome.
An important question raised by our results is how the
decrease in cellular ATP caused by the inhibition of glycolysis
and mitochondrial respiration by GPA and PA cotreatment
results in suppression of EGF-stimulated filopodia protrusions
in A431 cells. The molecule Profilin may hold the key to this
answer. Profilin is critical role for filopodia protrusion because
it promotes polymerization of filamentous actin (F-actin) at the
extending ends of filopodia (Witke, 2004).
Profilin binds to ADP-bound actin monomers, promotes
exchange of ADP for ATP, and releases ATP-actin at the growing
ends of F-actin, leading to polymerization of actin in a straight-
lined form (Le Clainche and Carlier, 2008; Witke, 2004). The
profilin-mediated elongation of F-actin bundles pushes the
cell membrane outward, resulting in the protrusion of spike-
shaped filopodia. In this regard, ATP provides the energy for
Profilin-mediated filopodia protrusion. Moreover, Molitoris
et al. observed that ATP depletion resulted in punctate disper-
sion of F-actin from its straight-lined form (Molitoris et al.,
1991), suggesting that stabilization of straight-lined F-actin
depends on the level of ATP in the cell. Therefore, one possible
explanation for the inhibition of filopodia protrusion by GPA
and PA cotreatment might be the lowering of intracellular ATP
concentration caused by the blockage of glycolysis by GPA
and mitochondrial respiration by PA.
Our study was based on the screening of crude natural prod-
ucts and bioassay-guided isolation of the components that
inhibit filopodia protrusion. Recently, natural product screening
has declined in popularity, probably because the isolation and
structural determination steps are costly and time consuming.
However, we believe our use of this technique to isolate com-
pounds that act synergistically to inhibit an important cellular
process demonstrate that crude natural product screening is still
a valuable technique. Since cellular responses are driven by
many complex systems that are often robust due to the presence
of rescue and feedback pathways, the best strategy for finding
bioactive inhibitors of a particular cellular system may be global
screening of crude extracts of natural products. In conclusion,
though the approach in this study may be deemed ‘‘old-fash-
ioned’’ and somewhat laborious, we believe the results provided
here have opened the broad avenue of natural products
screening for the continued progress in chemical genetics
research.996 Chemistry & Biology 17, 989–998, September 24, 2010 ª2010 ElSIGNIFICANCE
This study began with the natural product screening to
obtain the unique bioactive compounds. To obtain the
unique bioactive compounds, filopodia seem a good target
for the inhibitor screening from microbial origin because
of few inhibitors in reports. Moreover, filopodia in tumor
cells contribute to the metastasis; therefore, such inhibitor
holds the therapeutic impacts for the tumor treatment.
By screening the microbial broth, we found the cultured
broth of one Lechevalieria sp. strain that inhibited the
tumor filopodia protrusion. However, this inhibition disap-
peared following silica-gel chromatography. Interestingly,
the inhibitory activity was almost completely recovered by
remixing all of the silica-gel chromatography fractions, sug-
gesting that the inhibition required the synergistic effect of
two or more compounds contained within the microbial
broth that eluted in different fractions. We tried to isolate
the components responsible for inhibition of filopodia
protrusion and found glucopiericidin A (GPA) and piericidin
A (PA). PA is a known inhibitor of mitochondrial respiration,
but the mode of action of GPA has not yet been reported.
Our experiments with CE-TOFMS metabolomic analysis
showed that GPA suppressed glycolysis and identified
glucose transporters as the functional target molecule of
GPA. Importantly, GPA is glucopyranoside derivative of
mitochondrial respiratory inhibitor PA. This glycosidation
of PA into GPA lost the inhibitory activity to mitochondrial
respiration but gained the inhibitory activity to glucose
uptake, which would be informative to chemists to control
the inhibitor target between glucose transporter and mito-
chondrial respiration by a simple glycosidation. Finally, we
found that GPA-mediated inhibition of glycolysis dramati-
cally decreases intracellular ATP levels onlywhenmitochon-
drial respiration is inhibited, and concluded that this ATP
decrease caused the synergistic filopodia inhibition by
GPA and PA. In the end, this is the first report, to our knowl-
edge, on the novel use of CE-TOFMS metabolomic analysis
to isolate the target protein of the natural product inhibitor.EXPERIMENTAL PROCEDURES
Filopodia Protrusion Assay and ATP Determination
Cells were seeded sparsely at 5 3 104 cells ml-1 (250 ml per well in 48-well
plates. Sparse cell seeding was maintained throughout this study). After
1 day, the growth media was changed to CS 0.2% DMEM and the cells
were incubated for 12–18 hr. Cells were then treated with the assay samples
for 30 min, followed by stimulation with 30 ng ml1 of EGF (Sigma) for
30 min and observed under microscopy.
For screening, isolation from the broth, and evaluation of compounds, cells
with complete absence of filopodia were judged to be filopodia inhibited. To
quantify the filopodia cell population, filopodia protrusion was induced in the
same manner as above except that cells were seeded on glass coverslips in
12-well plates. The cells formed colonies on the coverslips, and filopodia
cell colonies were then counted. Colony counts were done in nine fields
chosen at random for one sample.
Cellular ATP levels were determined using an ATP assay kit (Sigma) after
cells had been treated for 30 min with test compounds.
For the test of inhibitors of mitochondrial respiration, concentrations of
100 nM rotenone, 10 ng ml-1 of antimycin A, and 10 ng ml-1 of oligomycins
were used.sevier Ltd All rights reserved
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Cells grown in 100 mm dishes were incubated in serum-reduced media for
18 hr and then treated with test compounds for 30 min. After washing cells
twice with ice-cold 5% mannitol, metabolites were extracted by keeping cells
resting on ice for 10 min in 1 ml of ice-cold methanol containing internal
standards (25 mM each of 3-aminopyrrolidine [Aldrich], L-methionine sulfone
[Wako], trimesate [Wako], and MES [Wako]). Extracts were then transferred
to a separate tube and mixed with 500 ml of milli-Q water, and 600 ml of this
solution was transferred into another tube, mixed with 400 ml of chloroform,
and centrifuged. A 300 ml aliquot of the aqueous layer was centrifugally filtered
through a 5 kDa cutoff membrane (Millipore) to remove proteins from samples.
The filtrate was lyophilized, dissolved in 50 ml of milli-Q water, and subjected
to CE-TOFMS analysis.
For the [13C]-isotope labeling study, culture media was changed to glucose-
depleted DMEMafter 18 hr incubation in serum-reducedmedia, and cells were
treated with 1 mg ml1 of [1,2,3,4,5,6-13C]-glucose (Isotec) immediately after
the test compounds addition. Metabolites were extracted after 30 min.
For the clear measurement of glucose-6-phosphate, fructose-6-phosphate,
and glucose-1-phosphate, LC-MS systems were also used. Details of
the metabolomic analysis are discussed in Supplemental Experimental
Procedures.
In Vitro Hexokinase Assay
Hexokinase is very active when the enzyme is bound to mitochondria (Floridi
et al., 1981); therefore, hexokinase was isolated from crude mitochondria
as described by Floridi et al., with minor modifications.
Small fragments of bovine heart in MSH buffer (210 mM mannitol, 70 mM
sucrose, 1 mM EGTA, 1 mM DTT, 0.1% BSA and 10 mM HEPES [pH 7.4])
were homogenized with a Dounce Tissue Grinder and centrifuged at 1000 3
g for 10 min. The supernatant was further centrifuged at 8000 3 g for
20 min. The resulting pellet was homogenized in MSH buffer and centrifuged
again. The crude mitochondria pellet was homogenized and stored at
80C until used.
For the measurement of hexokinase activity, G6PDH (Sigma) was used to
generate NADPH from the product of the hexokinase reaction. Hexokinase
activity was spectrophotometrically determined from the absorbance of
NADPH at 340 nm (Bergmeyer, 1963). The reaction mixture contained 30 mg
of bovine heart mitochondria, 1 mM ATP, 0.5 mM NADP+, 2 mM rotenone
(Calbiochem), 3 mg ml1 oligomycins (Calbiochem), and 0.1 units of G6PDH
in 100 ml of PT buffer (10 mM MOPS, 200 mM sucrose, 5 mM succinate,
1 mM Pi, and 0.01 mM EGTA [pH 7.4]). The reaction was initiated by addition
of 0.2 mM glucose at room temperature after a 10 min preincubation period.
The level of NADPH was continuously recorded for 20 min.
Uptake of [3H]-2-Deoxyglucose
Serum-starved A431 cells in DMEM containing 1.2 mM glucose were treated
with test compounds along with 0.5 mCi of [1,2-3H]-2-deoxy-D-glucose ([
3H]-
2DG, specific activity 50–60 Ci mmol-1, ARC) for 30 min, washed twice with
ice-cold PBS, and lysed with 0.5 N NaOH. Cell lysate radioactivity was
measured on a liquid scintillation counter.
Swiss 3T3-L1 preadipocytes were differentiated into adipocytes as
described (Saito et al., 2007). Adipocytes were pretreated with or without
insulin (100 nM, Sigma) for 15 min for GLUT4 translocation, and then treated
with test compounds and [3H]-2DG for 5 min for the glucose uptake study.
Other conditions were the same as described above.
To test GPA sensitivity toGLUT1 overexpression, HEK293T cells were trans-
fected with glut1 (derived from A431 cells) using lipofectamine. In the uptake
study, an HEK293T cell suspension was used because the cells are easily
detached from the culture plates and it was quite difficult to wash cells imme-
diately to terminate the uptake reaction. After 36 hr from transfection, cells
were left in PBS containing 1 mM EDTA for the gentle detachment. A suspen-
sion of 2.0 3 105 cells in 200 ml of glucose-free DMEM in a tube was treated
with test compounds and [3H]-2DG in a 25C water bath for 5 min. Glucose
uptake was terminated by the addition of ice-cold high glucose solution (final
25 mM), followed by centrifugation at 1000 3 g at 4C for 5 min. Cell pellets
were washed once with ice-cold high glucose solution and lysed with 0.1 N
NaOH. [3H]-2DG uptake under this condition linearly increased for at least
30 min.Chemistry & Biology 17, 989–9SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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